Compelling economic evidence is essential when bringing a product to market or increasing adoption in a challenging financial landscape.

Payers often aim to either reduce costs or increase their income and profitability whilst under pressure to improve service delivery and patient care – often through using the newest technology, which can be costly. It is more important now than ever to clearly demonstrate the value of a product.

We have conducted economic analyses for investors, Health Technology Assessment submissions, scientific publications, grant-funded projects, business cases, and national tariffs. Results have also been used to inform internal commercial prioritisation and strategy, reimbursement decisions, policy setting, and to raise internal and external awareness with stakeholders.

Our team employs rigorous analytical techniques and approaches including economic modelling, statistical analyses, econometrics, dynamic infectious disease modelling, systems thinking, operations research, financial modelling, optimisation, and discrete event models.

Get in touch to discuss how we can help you.